A Tamer 'Wildcard'? Antibiotic Exclusivity Would Have More Strings Attached In New Bill

Advocates for antibiotic incentives are hoping to attach 'wildcard' patent proposal to pending PAHPA reauthorization bill; New conditions on exclusivity are intended to make approach more politically viable – and assure favorable CBO score.

Washington DC Capitol dome detail with waving american flag

A new effort in the US Congress to enact a “wildcard” patent incentive to encourage antibiotic development would require companies who sell the exclusivity to contribute 5% of the proceeds to support early-stage antimicrobial research through the Foundation of the National Institutes of Health.

Reps. John Shimkus (R-Ill.) and Tony Cardenas (D-Calif.) plan to offer the “Revaluing Antimicrobial Products Act of 2018” (REVAMP)...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legislation

More from Pink Sheet